Bristol-Myers Squibb

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Bristol-Myers Squibb 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BMY

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. 

CEO
Christopher S. Boerner
CEOChristopher S. Boerner
Employees
32,500
Employees32,500
Headquarters
Princeton, New Jersey
HeadquartersPrinceton, New Jersey
Founded
1933
Founded1933
Employees
32,500
Employees32,500

BMY Key Statistics

Market cap
130.81B
Market cap130.81B
Price-Earnings ratio
14.42
Price-Earnings ratio14.42
Dividend yield
3.83%
Dividend yield3.83%
Average volume
15.88M
Average volume15.88M
High today
$66.49
High today$66.49
Low today
$63.26
Low today$63.26
Open price
$64.81
Open price$64.81
Volume
14.12M
Volume14.12M
52 Week high
$68.10
52 Week high$68.10
52 Week low
$42.52
52 Week low$42.52

Stock Snapshot

Bristol-Myers Squibb(BMY) stock is priced at $63.65, giving the company a market capitalization of 130.81B. It carries a P/E multiple of 14.42 and pays a dividend yield of 3.83%.

During the trading session on 2026-08-06, Bristol-Myers Squibb(BMY) shares reached a daily high of $66.49 and a low of $63.26. At a current price of $63.65, the stock is +0.6% higher than the low and still -4.3% under the high.

Trading activity shows a volume of 14.12M, compared to an average daily volume of 15.88M.

The stock's 52-week range extends from a low of $42.52 to a high of $68.10.

The stock's 52-week range extends from a low of $42.52 to a high of $68.10.

BMY News

Simply Wall St 5h
Bristol Myers Squibb Stock Looks Reasonable Below Fair Value

Bristol-Myers Squibb stock has delivered a 48.8% return over the past year, yet current checks still point to a company that screens as undervalued on both intr...

Bristol Myers Squibb Stock Looks Reasonable Below Fair Value
Investing.com 13h
Bristol Myers Squibb launches myeloma awareness campaign - Investing.com

...

Bristol Myers Squibb launches myeloma awareness campaign - Investing.com
TipRanks 16h
Midday Fly By: SpaceX slips, Disney reports earnings beat

The major averages were mixed near noon, with the Dow up nearly 400 points as investors weigh another wave of corporate earnings against continued geopolitical...

Analyst ratings

61%

of 31 ratings
Buy
35.5%
Hold
61.3%
Sell
3.2%

More BMY News

Seeking Alpha 20h
Bristol-Myers falls on report there are no talks going on with AstraZeneca

Bristol-Myers Squibb (BMY) dropped 1.4% in premarket trading after a report that there are no discussions happening with AstraZeneca (AZN) about a potential dea...

Bristol-Myers falls on report there are no talks going on with AstraZeneca
Barron's 2d
AstraZeneca-Bristol Myers: The Floodgates for Biotech Mergers Are Open

Biotech and Pharma Feature AstraZeneca-Bristol Myers: The Floodgates for Biotech Mergers Are Open In this article BMY 524715 LLY AZN ABBV Bristol Myers Squibb a...

AstraZeneca-Bristol Myers: The Floodgates for Biotech Mergers Are Open
TipRanks 3d
Bristol-Myers Squibb Clears Key Heart-Safety Milestone for BMS-986278

Bristol-Myers Squibb Company (BMY) announced an update on their ongoing clinical study. Unlock powerful investing tools with TipRanks Premium to make smarter,...

Seeking Alpha 3d
Potential AstraZeneca purchase of Bristol-Myers unlikely for now - analyst

A potential AstraZeneca (AZN) acquisition of Bristol-Myers Squibb (BMY) is unlikely to happen now after a report that the pharma giants have held deal talks, ac...

Potential AstraZeneca purchase of Bristol-Myers unlikely for now - analyst
MarketWatch 3d
AstraZeneca tie-up talks with Bristol-Myers Squibb are moving stocks. Analysts are puzzled.

“Odd” is the word analysts are using to describe a potential Bristol-Myers Squibb tie-up with AstraZeneca. AstraZeneca shares were slumping while Bristol Myers...

AstraZeneca tie-up talks with Bristol-Myers Squibb are moving stocks. Analysts are puzzled.
TipRanks 6d
Bristol-Myers Squibb: Strong Q2 Beat, Intact Pipeline Support Buy Rating as Jason Gerberry Raises Price Target from $66 to $71

Bank of America Securities analyst Jason Gerberry reiterated a Buy rating on Bristol-Myers Squibb yesterday and set a price target of $71.00. Claim 55% Off TipR...

Nasdaq 6d
Bristol-Myers Squibb Q2 2026 Earnings Call Transcript

AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX AD...

Bristol-Myers Squibb Q2 2026 Earnings Call Transcript

People also own

Based on the portfolios of people who own BMY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.